Table 2. IC values calculated for the investigated compounds.
|
Transfected cells
|
Parental cells
|
|||||
|---|---|---|---|---|---|---|
| Compounds | IC10 μM±s.d. | IC50 μM±s.d. | IC90 μM±s.d. | IC10 μM±s.d. | IC50 μM±s.d. | IC90 μM±s.d. |
| Betti-base | 5.0±4.4 | 40.2±4.5 | 75.3±5.2 | 0.5±0.1 | 4.1±0.2 | 35.3±8.3 |
| Tylosin | 133.1±52.8 | 410.0±31.8 | 885.4±51.0 | 76.1±49.4 | 561.3±66.4 | 1046.3±182.4 |
| TBN | 11.1±9.2 | 41.4±6.8 | 55.2±2.5 | 9.4±4.4 | 40.3±2.7 | 71.3±1.3 |
| Doxorubicin | 0.02±0.01 | 1.8±0.5 | 14.6±1.7 | 0.005±0.001 | 0.022±0.2 | 0.359±0.05 |
Abbreviation: TBN=N-tylosil-1-α-amino-(3-bromophenyl)-methyl-2-naphthol.
Non-resistant (parental cells) and human MDR1 gene-transfected (transfected cells) L5178 mouse lymphoma cells were treated with different concentrations of the compounds or vehicle and incubated in cell culture plates at 37°C for 72 h. At the end of the incubation period, the relative cell density was determined using an MTT assay and optical density reading. From the inhibitory curves obtained, corresponding IC10, IC50 and IC90 values were calculated.
Mean and s.d. values were calculated from at least three independent experiments.